What is the recommended treatment for an adult patient with an infection caused by ESBL‑producing organisms?

Treatment of ESBL-Producing Infections

Carbapenems are the first-line treatment for serious ESBL-producing infections, with ertapenem 1g IV daily preferred for most community-acquired infections and meropenem or imipenem-cilastatin reserved for healthcare-associated infections or septic shock. 1, 2

Treatment Selection Based on Infection Severity and Site

Uncomplicated Lower Urinary Tract Infections (Cystitis)

• Fosfomycin 3g single oral dose is the preferred first-line agent, achieving >95% susceptibility against ESBL-producing E. coli with minimal disruption of normal flora 1, 2
• Nitrofurantoin 100mg twice daily for 5-7 days is an effective alternative with >90% susceptibility against ESBL-producing E. coli, but cannot be used for Klebsiella species or upper UTIs 1, 2
• Pivmecillinam 400mg twice daily for 3-7 days is another option where available 1
• Never use fluoroquinolones, trimethoprim-sulfamethoxazole, or standard cephalosporins even if in vitro susceptibility suggests otherwise, as clinical failure rates are unacceptably high 1, 2

Complicated UTIs and Pyelonephritis

• Ertapenem 1g IV once daily is the preferred carbapenem due to convenient once-daily dosing and excellent ESBL coverage 1, 2
• Meropenem or imipenem-cilastatin are alternatives when broader coverage is needed 1
• Treatment duration is 10-14 days for pyelonephritis, extending to 14 days in males when prostatitis cannot be excluded 1, 2
• Replace any indwelling urinary catheter within 24 hours of starting therapy to eliminate biofilm-associated organisms 1

Intra-Abdominal Infections

For community-acquired infections with ESBL risk factors:

• Ertapenem 1g IV daily is preferred for patients with recent antibiotic exposure (particularly third-generation cephalosporins or fluoroquinolones within 90 days) or known ESBL colonization 3
• Eravacycline 1mg/kg IV every 12 hours is an alternative in beta-lactam allergic patients 3
• Treatment duration is 5-7 days after adequate source control 1

For healthcare-associated infections or septic shock:

• Meropenem 1g IV every 6 hours by extended infusion or continuous infusion is recommended 3
• Doripenem 500mg IV every 8 hours by extended infusion or imipenem-cilastatin 500mg IV every 6 hours by extended infusion are alternatives 3
• Treatment duration is 7-14 days depending on source control adequacy 3

Bacteremia

For ESBL bacteremia:

• Group 2 carbapenems (meropenem, imipenem-cilastatin, or doripenem) are the drugs of choice, not ertapenem when Pseudomonas or Enterococcus co-infection is possible 1
• Treatment duration is 10-14 days minimum, extending to 4-6 weeks for complicated bacteremia with persistent positive cultures >72 hours, septic thrombosis, or metastatic infection 1
• Obtain repeat blood cultures to document clearance of bacteremia 1

For severe sepsis or septic shock:

• Initiate dual gram-negative coverage with meropenem plus amikacin 15-20mg/kg IV daily until clinical stability is achieved 1
• De-escalate to meropenem monotherapy once susceptibility confirms ESBL (not carbapenemase) and patient improves 1

Critical Pitfalls to Avoid

• Piperacillin-tazobactam should NOT be used for bacteremic ESBL infections despite possible in vitro susceptibility, as outcomes are inferior to carbapenems 1, 4
• For non-bacteremic pyelonephritis, recent evidence suggests piperacillin-tazobactam may be reasonable and could reduce carbapenem-resistant organism emergence, but this remains controversial 5
• Cephalosporins including cefepime must be avoided for ESBL infections regardless of in vitro susceptibility due to well-documented clinical failures 1, 2, 4
• Do not treat asymptomatic bacteriuria in patients with chronic catheters, as persistent bacteriuria is expected and does not require antibiotics 1

Carbapenem-Sparing Strategies for Select Situations

• Ceftazidime-avibactam 2.5g IV every 8 hours shows excellent activity against ESBL-producing organisms and can be used as a carbapenem-sparing option for mild-to-moderate infections when susceptibility is confirmed 3, 1
• Ceftolozane-tazobactam is effective against ESBL-producing Enterobacteriaceae and may preserve carbapenems 1
• These newer agents should be reserved for carbapenem-resistant infections or carbapenem-sparing strategies in stable patients, not routine ESBL treatment 1

Monitoring and Clinical Response

• Assess clinical response within 48-72 hours of initiating therapy 1, 2
• Obtain blood cultures before starting therapy in any patient with fever or systemic signs 1
• Escalate to parenteral therapy immediately if fever, flank pain, or systemic symptoms develop, or if no clinical improvement occurs within 48-72 hours of oral therapy 1
• Local antimicrobial resistance patterns should guide empiric therapy decisions before culture results are available 1, 2